New Jersey-based pharmaceutical giant Celgene announced Sunday it will acquire two-year-old San Diego startup Impact Biomedicines in a deal that could ultimately be worth more than $2.35 billion. Impact Biomedicines is developing the fedratinib drug for treating myelofibrosis and polycythemia vera, two rare bone marrow cancers. Celgene will pay approximately $1.1 billion upfront and up […]